154 related articles for article (PubMed ID: 18317968)
1. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
Neyns B; Chaskis C; Joosens E; Menten J; D'Hondt L; Branle F; Sadones J; Michotte A
Cancer Invest; 2008; 26(3):269-77. PubMed ID: 18317968
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
Yung WK; Prados MD; Yaya-Tur R; Rosenfeld SS; Brada M; Friedman HS; Albright R; Olson J; Chang SM; O'Neill AM; Friedman AH; Bruner J; Yue N; Dugan M; Zaknoen S; Levin VA
J Clin Oncol; 1999 Sep; 17(9):2762-71. PubMed ID: 10561351
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
Chamberlain MC; Tsao-Wei DD; Groshen S
Cancer; 2006 Jan; 106(1):172-9. PubMed ID: 16323194
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
6. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Chamberlain MC
Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Chamberlain MC; Wei-Tsao DD; Blumenthal DT; Glantz MJ
Cancer; 2008 May; 112(9):2038-45. PubMed ID: 18361434
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Chan DT; Poon WS; Chan YL; Ng HK
Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
Nishikawa R; Shibui S; Maruno M; Sugiyama K; Sato S; Fujimaki T; Takahashi H; Wakabayashi T; Takahashi J; Kochi M; Nakamura H; Sawamura Y; Ikeda J; Hori T; Aoki T; Matsutani M
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1279-85. PubMed ID: 16969025
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
16. Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.
Koch D; Wick W
J Neurooncol; 2006 Apr; 77(2):219-20. PubMed ID: 16292485
[No Abstract] [Full Text] [Related]
17. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
van den Bent MJ; Taphoorn MJ; Brandes AA; Menten J; Stupp R; Frenay M; Chinot O; Kros JM; van der Rijt CC; Vecht ChJ; Allgeier A; Gorlia T;
J Clin Oncol; 2003 Jul; 21(13):2525-8. PubMed ID: 12829671
[TBL] [Abstract][Full Text] [Related]
19. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Strowd RE; Abuali I; Ye X; Lu Y; Grossman SA
J Neurooncol; 2016 Mar; 127(1):165-71. PubMed ID: 26729269
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]